Gestodene

BRAND NAMES

1. Femodene / Femoden / Femodette: Widely recognized international formulations

2. Minesse / Mirelle: Ultra–low dose preparations containing gestodene with ethinylestradiol

3. Gynera / Minulet: Common ethinylestradiol-based combination contraceptives

4. Meliane / Harmonet: Frequently include gestodene with ethinylestradiol

5. Other brands: Triodene, Katya, Millinette, Lindynette, Logest, Avaden, Avadene, and Convaden

MECHANISM OF ACTION

Gestodene is a potent synthetic progestin that prevents pregnancy primarily by suppressing ovulation through inhibition of the hypothalamic–pituitary–ovarian axis. It reduces the secretion of gonadotropins, particularly luteinizing hormone (LH), thereby preventing the LH surge required for ovulation. In addition, it thickens cervical mucus, making it more difficult for sperm to penetrate the cervix, and induces changes in the endometrium that reduce the likelihood of implantation. When used in combination with estrogen (such as ethinylestradiol), these effects are enhanced, resulting in effective hormonal contraception.

PHARMACOKINETICS

Absorption: Gestodene is quickly and almost completely absorbed following oral administration, with an absolute bioavailability of nearly 100%.

Distribution: It has a strong affinity for sex hormone-binding globulin (SHBG), with approximately 64–75% bound to SHBG, 24–34% bound to albumin, and only about 0.6–1.3% circulating in the unbound (free) form. Long-term use, especially with ethinylestradiol, increases SHBG levels, leading to higher total serum concentrations.

Metabolism: It is extensively metabolized in the liver mainly through reduction and hydroxylation pathways and is not solely dependent on CYP3A4. It is not a prodrug.

Elimination: The terminal elimination half-life is approximately 12–18 hours. During continuous use, increased SHBG levels result in reduced total clearance compared to single-dose administration.

PHARMACODYNAMICS

Gestodene is a highly potent third-generation progestin used in combined oral contraceptives. It exhibits strong progestogenic activity with weak androgenic effects, along with mild antimineralocorticoid and glucocorticoid properties. Its contraceptive action is achieved by suppressing ovulation, increasing the thickness of cervical mucus to hinder sperm penetration, and modifying the endometrial lining to prevent implantation. Due to its high potency and bioavailability, it is effective at relatively lower doses compared to earlier progestogens.

DOSAGE AND STRENGTH

• Commonly used in low-dose combined oral contraceptives (COCs)

• Typically combined with ethinylestradiol

• Frequent formulations include 75 mcg gestodene + 20 mcg or 30 mcg ethinylestradiol

• Other available strengths include 60 mcg gestodene + 15 mcg ethinylestradiol

Administration:

• Administered orally as a single tablet once daily, ideally taken at the same time every day.

• Can be taken with or without food

Regimen types:

• 21-day cycle: 21 active tablets followed by a 7-day pill-free interval

• 24-day cycle: 24 active tablets followed by 4 placebo tablets

FOOD INTERACTIONS

Gestodene, commonly used together with ethinylestradiol in oral contraceptives, may have potential interactions with certain foods, beverages, and dietary supplements that can influence its effectiveness or increase the likelihood of side effects.

DRUG INTERACTIONS

Gestodene is a potent progestin used in combined oral contraceptives that can be affected by drugs which induce hepatic enzymes, such as rifampicin, phenytoin, and carbamazepine, leading to reduced contraceptive effectiveness. It is mainly metabolized through CYP3A4, and while inhibitors like ketoconazole may have limited impact, other substances particularly herbal products such as St. John’s Wort can significantly lower its plasma levels and compromise its efficacy.

CONTRAINDICATIONS

Gestodene, a third-generation progestin used in combined oral contraceptives, is contraindicated in women who have an increased risk of venous or arterial thromboembolism, including those over 35 years of age who smoke, patients with severe hypertension, diabetes with vascular complications, or a history of blood clots. It is also not recommended in individuals with active liver disease, known or suspected hormone-dependent cancers such as breast cancer, unexplained vaginal bleeding, or those receiving certain hepatitis C antiviral treatments.

SIDE EFFECTS

• Common effects: Headache, nausea, abdominal discomfort, and breast tenderness.

• Menstrual changes: Irregular bleeding, spotting, or variations in menstrual flow.

• Hormonal effects: Mood changes, irritability, or depression

• Skin effects: Acne or, in some cases, skin improvement depending on individual response

• Breast effects: Breast enlargement or tenderness

• Serious but rare effects: Increased risk of venous thromboembolism (blood clots), hypertension, and liver-related complications

• Other effects: Decreased libido or changes in sexual desire

OVERDOSE

An overdose of Gestodene, a synthetic progestogen used in oral contraceptives, is usually not life-threatening. Since it is commonly formulated with ethinylestradiol, overdose effects typically reflect the combined hormonal actions of both components.

TOXICITY

Gestodene, a third-generation progestin used in combined oral contraceptives, is generally well tolerated but is associated with certain toxicity concerns. The most important risk is an increased likelihood of venous thromboembolism (blood clots) compared with older progestins. It may also contribute to liver-related adverse effects in susceptible individuals. In addition, as a synthetic hormone, it can have significant ecological toxicity, particularly affecting aquatic organisms.